SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (16446)4/12/2005 11:38:07 PM
From: Biomaven  Respond to of 52153
 
Thanks tuck. Diabetes is a good target for "chronic" personalized medicine given that patients have to be treated for years and current treatments are all marginal. It's clearly worth spending some dollars upfront to get the right treatment for a patient, assuming of course that the drug works well in some identifiable subset of patients.

Note the PPAR agonists as a class have all suffered a delay with the FDA last year asking for longer toxicity testing.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News